CD19 and neoplasm: One example is the a bromodomain and extra-terminal motif (BET) protein inhibitor JQ-1, which enabled enrichment of human CD19 CAR T cells with TSCM and TCM phenotypes as well as superior in vivo persistence and anti-tumor effects (71).